FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara PYZCHIVA becomes Samsung Bioepis’ seventh biosimilar and fourth immunology biosimilar approved by the FDAPYZCHIVA’s licensing period will begin on February 22, 2025, in the United States, based on the...

When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK… Exton, Pennsylvania, Nov. 30, 2023 (GLOBE NEWSWIRE) -- With the Ulcerative Colitis (UC) market set to heat up in the coming months, the JAK class seems poised to become a dominant treatment,...

Global Crohn's Disease Forecast and Market Analysis Report 2020-2027 - Despite Formulary Constraints, Novel Pipeline Drugs will Expand the Market Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Crohn's Disease Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering. As specialty products, therapies...